Here's some of what is coming soon to NeurologyLive® this week.
News|Articles|January 5, 2026
FDA Action Update, December 2025: Acceptance, Approval, and Clearance
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in December 2025, making a number of decisions on potential new therapeutic agents, including accepting a new drug application, clearing the initiation of a clinical trial, granting an approval, pushing back a review, and expanding an indication.
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
Advertisement
Advertisement